HOME >> BIOLOGY >> NEWS
SEROQUEL: An effective treatment option for aggression in patients with schizophrenia

Alderley Park, UK, 17 June 2005 A new study, published today in the journal Human Psychopharmacology: Clinical and Experimental,1 shows that the atypical antipsychotic SEROQUEL (quetiapine), may be an effective treatment option for patients with schizophrenia who exhibit aggressive behaviour during psychotic episodes. In the study, patients who received SEROQUEL demonstrated significantly greater improvements in symptoms of aggression and hostility compared to patients receiving placebo (p<0.01 P<0.01 on Brief Psychiatric Rating Scale (BPRS) alternative hostility cluster score, one of three parameters derived from the BPRS to measure hostility symptoms in the study. ).

"Aggressive behaviour is a significant problem in patients with schizophrenia and has severe negative consequences for the patient, families, carers and the therapeutic community as a whole" commented Professor Celso Arango, from the Hospital General Universitario Gregorio Maranon, Madrid, Spain, and study author. "It is important that patients who are experiencing aggressive symptoms are prescribed a therapy which not only treats these symptoms but which they also find acceptable, in terms of its tolerability, so that they adhere to the prescribed treatment" continued Professor Arango. "In both respects, SEROQUEL holds advantages for both patient and clinician, making it a powerful treatment option for these distressing and challenging symptoms."

SEROQUEL has been shown to provide first line efficacy together with trusted tolerability in treatment of schizophrenia during three randomised, double-blind, placebo-controlled studies.2, 3, 4 The study published today, an analysis of pooled data from these three pivotal trials, included a total of 389 patients who exhibited aggressive behaviour at study entry. The results show that patients who received SEROQUEL demonstrated significantly greater improvements in symptoms of aggression and hostility, compared with patients ta
'"/>

Contact: Sarah Fraser
sarah.fraser@newyork.shirehealth.com
+1-212-329-6272
Shire Health International
17-Jun-2005


Page: 1 2

Related biology news :

1. Smokeless tobacco more effective than cigarettes for delivering dangerous carcinogens into the body
2. Developing a more effective vaccine for tuberculosis
3. Cost-effective method for gene silencing is featured in Cold Spring Harbor Protocols
4. Implanon, Norplant and Jadelle are all effective contraceptives -- but side effects vary
5. High blood pressure medication strategy proves effective in Hispanic women
6. New compound effectively treats fungal infections
7. Northern forests less effective than tropical forests in reducing global warming
8. Cisplatin is more effective than carboplatin for treating nonsmall cell lung cancer
9. Scientists develop new drugs to fight colon and breast cancer more effectively
10. Avian influenza survivors antibodies effective at neutralising H5N1 strain
11. Studies assess effectiveness of serotonin and nerve stimulants on irritable bowel syndromes

Post Your Comments:
(Date:6/25/2015)... LAKE CITY , June 25, 2015  Imagine ... first steps toward a healthier, happier life. That,s exactly ... is designed to do. The cutting-edge, portable health program ... offers real-life solutions to help improve your lifestyle and ... Association awards dinner and gala Wednesday night, USANA,s THA ...
(Date:6/24/2015)... , June 24, 2015 This report provides ... the next six years. It contains an analysis of ... along with their impact from the short, medium, and ... discusses the industry, market, and technology trends that currently, ... need of concerned authorities to efficiently manage the increasing ...
(Date:6/24/2015)... Biometry authentication provider KeyLemon today announced ... one face in. Logo - ... in, entering the expanding biometric authentication market in ... answer to the password problem. With advanced face ... KeyLemon, one face in allows users to securely ...
Breaking Biology News(10 mins):@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2
(Date:7/28/2015)... July 28, 2015 Seahorse Bioscience, the ... is the provider of XF Technology which is ... research areas. As the links between mitochondrial function ... metabolism is escalating rapidly.   Recently, ... Nature Publishing Group (NPG) featuring XF Technology, including ...
(Date:7/28/2015)... 2015 Deerfield Management Company, L.P. today announced ... which will invest in groundbreaking advancements in science that ... and orphan diseases. The venture capital fund will also ... developed and improve the way healthcare is delivered to ... healthcare-focused venture funds in the sector, will donate all ...
(Date:7/28/2015)... July 28, 2015 CSL Behring ... has accepted for review the company,s Biologics License Application ... (rVIII-SingleChain) for the treatment of hemophilia A. In the ... Hemophilia A is a congenital ... nearly all affected patients are male. People with hemophilia ...
(Date:7/27/2015)... , July 27, 2015  Amgen (NASDAQ: AMGN ... quarter financial results on Thursday, July 30, 2015, after ... will be followed by a conference call with the ... call from Amgen will be Robert A. Bradway ... of Amgen,s senior management team. Live audio ...
Breaking Biology Technology:XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 2XF Technology Used to Demonstrate Feasibility of Stem Cell Regenerative Technique 3Deerfield Launches $550 Million Healthcare Venture-Capital Fund 2Deerfield Launches $550 Million Healthcare Venture-Capital Fund 3U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3Amgen Announces Webcast of 2015 Second Quarter Financial Results 2
Cached News: